Agenus Inc (AGEN) Institutional Holdings & 13F Data (Q2 2026)

AI summary pending

AI summary pending

Agenus (AGEN) expanded its board of directors from six to seven seats and appointed Rome-based attorney Marco Tullio Marcucci as a Class II director, effective August 5, 2026. His term runs until the company's 2029 annual stockholder meeting, and he also joined the Corporate Governance and Nominating Committee. Marcucci will receive an annual cash retainer of $75,000, a $7,500 annual committee retainer, and an option to purchase 7,500 shares that vests in three equal annual installments beginning in August 2027. The filing says there were no arrangements or family relationships behind the appointment and no material interests requiring disclosure.

AI summary pending

Agenus Inc. entered into a securities purchase agreement with institutional and accredited investors, raising about $85 million through the sale of common stock (or pre-funded warrants) plus two series of warrants. If all warrants are exercised, the company could receive up to an additional $255 million. The warrants' exercise and transfer conditions are tied to milestones in the Phase 3 clinical trial of its colon cancer drug combination, botensilimab and balstilimab. The company also agreed to increase its board size to nine directors.

Agenus Inc. amended its existing debt and warrant agreements with holders of $5.09 million in notes originally issued in 2015, pushing the maturity date out eight months to February 2027 and extending the expiration of several warrant series, including A, B, and C warrants, to 2031. The company also issued new D warrants for up to 56,525 shares at $3.25 per share, and agreed to register the underlying shares for resale within 90 days. All other terms, such as the interest rate, remain unchanged.